Background: Permanent pacemaker implantation is the most common complication after
| INTRODUCTION
Historically, the management of valvular heart disease using a percutaneous route was limited to balloon angioplasty and was associated with a high rate of restenosis. 1 The successful use of transcatheter aortic valve replacement (TAVR) has opened up new horizons in the management of structural valve diseases. 2 Several randomized clinical trials have demonstrated the safety and efficacy of TAVR in both high operative risk and subsequently in intermediate risk patients. [3] [4] [5] These trials have also demonstrated adverse effects associated with the procedure. Disturbances in cardiac conduction have been identified as a common complication after TAVR, often requiring implantation of a permanent pacemaker (PPM). 6 The incidence of PPM implantation varies based on the type of valve used and ranges from 5% to 12%. [7] [8] [9] PPM implantation after TAVR has been associated with increased hospital length of stay, increased risk of mortality, and heart failure readmissions. 10 A cost analysis from the FRANCE registry showed that PPM implantation after TAVR was associated with a 36% increase in procedural costs and increased in-hospital costs compared to surgical aortic valve replacement. 11, 12 A recent study highlighted the importance of measuring qualityof-life (QoL) and health status outcomes in patients undergoing TAVR. 13 Their study found that functional outcomes are more desired among patients than life expectancy, despite multiple comorbid conditions and advanced age among the cohort. Hence, in addition to measuring survival and occurrence of major adverse cardiac events (MACE), assessment of QoL and health status outcomes is paramount in this population. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a patient-reported disease-specific health status survey that has been validated for assessment of functional status and QoL in patients undergoing TAVR. 13, 14 Changes in KCCQ score have also been shown to correspond well to New York Heart Association (NYHA) functional status and extent of clinical improvement. 15 However, it remains unclear if patients undergoing PPM after TAVR are likely to have improvement in QoL and overall health status.
To identify this outcome, our study aims to compare QoL outcomes in patients post-TAVR receiving pacemaker implantation to those without; while also determining factors that predict poor QoL outcomes and correlate that to the survival rates among the cohort at our tertiary care referral center. The study has the following key objectives: (i) to compare QoL outcomes among patients undergoing TAVR who did and did not undergo PPM implantation; (ii) to determine predictors of poor QoL outcomes among patients undergoing TAVR; (iii) to determine if patients experiencing poor QoL also have poor survival post-TAVR.
| ME TH ODS

| Study population
The study population was obtained from the prospective TAVR database, which comprised of consecutive patients who presented to our tertiary care center (Gates Vascular Institute, Buffalo, NY) and underwent TAVR from January 2012 to July 2016 and reviewed retrospectively. Those patients who had undergone prior PPM implantation were excluded from the study. All data were collected using the standardized definitions, which conforms to the standards of the Society of Thoracic Surgeons and American College of Cardiology's National Transcatheter Valve Therapy (TVT) registry. 16 All patients underwent routine follow-up post-TAVR, including KCCQ questionnaire during each visit, at 30 days and 1 year.
| Clinical characteristics
Baseline demographic data were collected on all the patients in the study. Additionally, relevant clinical variables including comorbid conditions and home medications were collected. Detailed procedural characteristics, laboratory data, and prior-noninvasive testing, including a routine electrocardiogram, were collected. Electrocardiographic (ECG) data obtained prior to TAVR included presence of a left bundle branch block (LBBB), right bundle branch block (RBBB), QRS duration, PQ interval, and the presence of atrial fibrillation. Post-TAVR PPM implantation and occurrence of postprocedure arrhythmia were recorded as well.
| Society of thoracic surgeons score
The Society of Thoracic Surgeons (STS) score for each patient was also included. The STS risk score is used to assess the risk of morbidity and mortality for common cardiac surgeries. It is one of the most commonly used risk scores for surgical patients. 17 The score is especially important in the TAVR population as most patients who undergo TAVR have an elevated STS score, thus classifying them as high surgical risk, making them a poor candidate for surgical aortic valve replacement. 18 Thus, the STS scores are one of the major factors considered in assessing patients for TAVR candidacy.
| Quality of life assessment
The QoL assessment was performed using the shortened KCCQ-12 questionnaire. The KCCQ is an international standard for quantification of disease-specific health status in patients with heart failure. 
| Statistical analysis
Categorical variables are reported as frequency (%), and comparison between groups was performed by chi-square tests of independence. 
| RESULTS
| Study population
We included 383 consecutive patients who underwent TAVR at our institution. The baseline characteristics of the patients are outlined in Table 1 . The mean age among all patients was 83 AE 8 years, and equal numbers of patients were men (n = 195, 51%) and women (n = 188, 49%). The majority of patients were Caucasians (n = 364, 95% 
| Procedural characteristics
The transfemoral route was the most common access site (361, 94%) among all patients undergoing TAVR. As shown in Table 2 Table 3 outlines the presence of baseline ECG abnormalities among patients who underwent PPM compared to those not requiring PPM post-TAVR. Among all patients, atrial fibrillation was the most common abnormality on ECG. LBBB and QRS duration > 150 ms did not differ among those with and without PPM. However, the presence of RBBB on preprocedure ECG was significantly higher among patients who underwent PPM post-TAVR. Similarly, the presence of a PQ interval > 250 ms was higher in patients undergoing PPM post-TAVR, as shown in Table 3 .
| Baseline electrocardiographic abnormalities
| Quality of life outcomes
Among all patients, the median KCCQ-12 score prior to TAVR was Values are mean AE standard deviation, median (Interquartile range), N (%). 
| Predictors of poor QoL outcomes
Univariate analysis was performed to identify patient characteristics and risk factors that were associated with a poor QoL outcome post-TAVR and are outlined in 
| Poor QoL and adverse events
In unadjusted analysis, those patients with poor QoL outcomes at 1 month post-TAVR follow-up also had significantly higher all-cause mortality post-TAVR (31.3% vs 4.5%, P < .001) and MACE (33.3% vs F I G U R E 1 Kansas City Cardiomyopathy Questionnaire (KCCQ)-12 scores among patient with and without pacemaker at 1 mo and 1 y post-transcatheter aortic valve replacement (TAVR). The median KCCQ-12 score at 1 mo post-TAVR was significantly lower among patients undergoing pacemaker implantation. However, at 1 y, the KCCQ-12 score was similar among those with and without pacemaker implantation the Kansas City Cardiomyopathy Questionnaire (KCCQ). 15, [23] [24] [25] [26] The "KCCQ-12" questionnaire is a shortened version, which has been validated in both stable and acute heart failure recovery patients 20 and is incorporated as a QoL metric that is obtained as part of the TVT registry prior to TAVR and at 1 month, 6 months, and 1 year post-TAVR, respectively. Although a growing body of evidence has demonstrated improvement in QoL outcomes after TAVR, 27,28 the follow-up is usually short and patients lost to follow-up due to poor outcomes may create a potential for bias in these studies. In our study, we demonstrated significant improvement in QoL during both short-term (1 month) follow-up and during long-term follow-up at 1 year post-TAVR.
Pvalue
| QoL and pacemaker implantation post-TAVR
Heart block requiring PPM is the most common complication post-TAVR 6 and is associated with adverse outcomes and increased mortality. 8,10,11 However, there is no data evaluating the QoL outcomes after PPM in this cohort. Our study is unique in being the first of its kind to assess the impact of postprocedure PPM on QoL outcomes.
We demonstrated that patients undergoing PPM had worse QoL during short-term (1 month) assessment of KCCQ-12 scores. However, during long-term (1 year) assessment, we did not find any differences in the QoL among those with and without PPM. We hypothesize that the initial low QoL metrics are secondary to PPMrelated issues (ie, postprocedure pain, limitations in range of motion of the arms, bleeding complications, postprocedure infections, etc.).
However, upon subsequent resolution of these issues, patients with PPM actually had slightly higher KCCQ-12 scores during long-term follow-up. We also compared mortality and occurrence of complications including myocardial infarction and stroke at 1 month and 1 year, respectively. Among patients who underwent pacemaker implantation, we found no significant difference in occurrence of mortality and complications during short-(1 month) and long
(1 year)-term follow-up, suggesting that these factors did not play a As shown in our cohort, a high pre-TAVR STS score was also shown to be associated with lower postprocedural QoL measures. 31 Extent of severity of mitral regurgitation post-TAVR has been associated with poor QoL as well. 32 Taramasso et al 33 demonstrated
that the presence of residual moderate-to-severe paravalvular leak was associated with poor QoL metrics. Likewise in our cohort, the presence of mitral and tricuspid regurgitation and lower aortic valve area assessed by post-TAVR echocardiography were significantly associated with poor QoL outcomes. One study showed that female sex was associated with worse QoL measures at 3 months; however, it did not remain significant at 12 months post-TAVR. 34 In our cohort, female gender remained significantly associated with poor QoL at 1-year follow-up as well. Future studies evaluating gender disparities contributing to these findings are warranted.
| Poor QoL and mortality
Another key finding of our study was the association of poor QoL at 1 month post-TAVR and increased mortality at 1-year follow-up.
Even after adjusting for STS risk score, the presence of poor QoL after TAVR remained a strong predictor of increased mortality in our 
| Limitations
Although the data were collected prospectively, the retrospective evaluation of the study hypothesis creates a potential for selection bias. However, all the data are collected using the standardized definitions, which conforms to the standards of the STS ACC'S National TVT registry, which reduces the risk of selection bias. As it is a single-center experience, the results may not be representative of the general population. The study consists of a relatively small patient cohort especially in the nonagenarian group. However, our study is unique with equal representation of both sexes, which is not com- 
